Entries by Daniela Weiss

LSX World Congress 2019 – feeling the pulse of the industry

Back in January this year, Horton International UK, published its 2019 report on the European Life Sciences Market. The report stated that, “There was a belief that investment into the sector is likely to remain healthy and potentially grow, over the coming 12 months”. The optimism was, however, tempered by the uncertainties of the UK’s withdrawal […]

The European Life Sciences Market – continued growth despite the uncertainties of Brexit?

Earlier this month, Horton International (UK) launched its 2019 European Life Science Report, published following our annual survey among the movers and shakers within the European Life Science sector. Our report last year reflected a general feeling of optimism, suggesting that people thought the sector was in good shape and investment would continue to be healthy; by most […]

Make me a Vice President, and I’ll take the job!

Some time ago, I wrote an article entitled, “Location: the biggest challenge to talent management”, and talked about the challenges of relocation. As an international Executive Search organisation, we are constantly asked to carry out global searches to find “the best person for the job”, no matter where the people are located around the world. […]

The candidate you want or the candidate you need? The added value available from Executive Search Consultants

At first glance this question might appear presumptuous. It is a fundamentally important aspect of how a strong relationship with an Executive Search Partner can benefit an organisation. As Rob Briner, Professor of Organisational Psychology at the Queen Mary University of London’s School of Management, points out: “to say ‘we want the best person for […]

The European Life Sciences Market – looking forward to continued growth

Earlier this month, Horton International (UK) launched its 2017 European Life Science Report, published following our annual survey among the movers and shakers within the European Life Science sector. Our report last year, suggested a fall-off in optimism, especially when a number of questions compared it to the high-point of 2015-2016. Also, that survey was carried out around the same time as the UK Brexit vote, which may have made some of the UK respondents a little more cautious.

The outcome of this year’s survey seems to suggest that the fall off in optimism was merely a temporary hiatus, with practically all of our indicators suggesting that people think the sector is in good shape, and investment will continue to be healthy. It is interesting to note that not a single respondent felt there would be a decline in employment in the sector, and the “confidence indicator” (marks out of 10) rose from 6.5 last year to 7.4 this year, only just short of the record high figure of 7.7 in
2015. We could conclude that the sector has been (and remains) in good shape since 2014, and that 2016 was merely a year for everyone to draw breath.

The shadow of Brexit

Given that it is just over a year since the UK voted to leave the EU, it is not surprising that Brexit was raised as an issue, particularly for the UK respondents. Having seen the “confidence indicator” rise back up to 7.4, however, it does suggest that most of the people questioned do not expect Brexit to have a major impact on the growth of the industry. This was not the view of all the respondents, with one UK colleague saying “Brexit is a major challenge to the Life Sciences Industry, particularly if the “no deal with EU is preferable to a bad deal” rhetoric is fulfilled. I’m not convinced that the Government fully understands the challenge to medical technology companies of a Brexit deal that does not offer the same access to harmonisation of regulations, patents, grant funding, free movement of skilled people and collaboration with EU centres of clinical and academic excellence as presently enjoyed in this industry sector.”

The main findings in this year’s survey are as follows:

  • There is a belief that investment into the sector is likely to remain healthy, and potentially grow, over the coming 12 months.
  • Investors will be looking for new opportunities, as well as managing their existing portfolios.
  • IPOs will continue to be a viable route for companies to raise money in the coming year.
  • There is a general feeling that achieving an exit will prove to be no easier or no more difficult than in previous years.
  • There has been a continuing shift back to therapeutic proteins, with areas such as immune-oncology remaining one of the hot areas. The other area creating interest is around personalised medicine and digital health.
  • It is felt that there will be a continued increase in employment in the sector.
  • There is a general consensus that the European Life Sciences sector is robust and, notwithstanding a global crisis such as a financial crash, will continue to offer good returns for investors.

For a copy of the full report, please contact Paul Edwards at edwards@hortoninternational.com.


Paul Edwards
is the Managing Partner, Global Healthcare at Horton International, leaders in the Executive Search community.

How expert executive search consultants can bring value to not-for-profit recruitment

Not-for-profit organisations by their nature sometimes operate differently from other, commercial organisations, though, when it comes to recruiting senior level staff, many of the considerations are the same. Recruiting the best to the C-suite and senior management teams of charities and other non-profit organisations helps to deliver on their goals, and compromise in this respect, […]

P = MK² and the ambitious Executive

The library of information analysing the characteristics of successful Executives and CEOs is formidable but there are common themes that may be identified in much of the literature. A recent report from a large, global head-hunter entitled Unleashing “ridiculous” ambition, which looked at characteristics of “high performers” noted that they are “fuelled by an intense […]